Karnon, Jonathan <br/><br/>
Cost utility analysis of early adjuvant letrozole or anastrozole versus tamoxifen in postmenopausal women with early invasive breast cancer: the UK perspective.  [electronic resource] 

 -  The European journal of health economics : HEPAC : health economics in prevention and care  May 2008 
 - 171-83 p.  digital 
<br/><br/> Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1618-7598 
<br/><br/><label>Standard No.: </label>10.1007/s10198-007-0058-1  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Anastrozole<br/>Antineoplastic Agents--administration & dosage<br/>Antineoplastic Agents, Hormonal--administration & dosage<br/>Breast Neoplasms--drug therapy<br/>Cost-Benefit Analysis<br/>Female<br/>Humans<br/>Letrozole<br/>Markov Chains<br/>Neoplasm Recurrence, Local<br/>Neoplasms, Hormone-Dependent--drug therapy<br/>Nitriles--administration & dosage<br/>Postmenopause<br/>Quality of Life<br/>Randomized Controlled Trials as Topic<br/>Tamoxifen--administration & dosage<br/>Triazoles--administration & dosage<br/>United Kingdom--epidemiology